CA2966642C - Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma - Google Patents

Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma Download PDF

Info

Publication number
CA2966642C
CA2966642C CA2966642A CA2966642A CA2966642C CA 2966642 C CA2966642 C CA 2966642C CA 2966642 A CA2966642 A CA 2966642A CA 2966642 A CA2966642 A CA 2966642A CA 2966642 C CA2966642 C CA 2966642C
Authority
CA
Canada
Prior art keywords
compound
cpp
oat
treatment
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2966642A
Other languages
English (en)
French (fr)
Other versions
CA2966642A1 (en
Inventor
Richard B. Silverman
Yaron Ilan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
Northwestern University
Original Assignee
Hadasit Medical Research Services and Development Co
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Medical Research Services and Development Co, Northwestern University filed Critical Hadasit Medical Research Services and Development Co
Publication of CA2966642A1 publication Critical patent/CA2966642A1/en
Application granted granted Critical
Publication of CA2966642C publication Critical patent/CA2966642C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
CA2966642A 2014-11-07 2015-11-09 Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma Active CA2966642C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462076980P 2014-11-07 2014-11-07
US62/076,980 2014-11-07
PCT/US2015/059738 WO2016073983A2 (en) 2014-11-07 2015-11-09 Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma

Publications (2)

Publication Number Publication Date
CA2966642A1 CA2966642A1 (en) 2016-05-12
CA2966642C true CA2966642C (en) 2023-03-28

Family

ID=55910047

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2966642A Active CA2966642C (en) 2014-11-07 2015-11-09 Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma

Country Status (9)

Country Link
US (1) US9603820B2 (enExample)
EP (1) EP3215144B1 (enExample)
JP (1) JP6867949B2 (enExample)
AU (1) AU2015342801A1 (enExample)
CA (1) CA2966642C (enExample)
ES (1) ES2882126T3 (enExample)
IL (1) IL252042B (enExample)
MX (1) MX2017006022A (enExample)
WO (1) WO2016073983A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021519753A (ja) * 2018-03-29 2021-08-12 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 眼障害の治療における（１ｓ，３ｓ）−３−アミノ−４−（ジフルオロメチリデン）シクロペンタン−１−カルボン酸および（ｓ）−３−アミノ−４−（ジフルオロメチルエニル）シクロペンタ−１−エン−１−カルボン酸の使用
US10822301B2 (en) 2018-04-12 2020-11-03 Northwestern University 3-carbon substituted 4-aminocyclopent-1-ene-1-carboxylic acid compounds as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase
IL278932B2 (en) 2018-05-25 2024-03-01 Univ Northwestern PROCESS FOR THE SYNTHESIS OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-l-ENE-l-CARBOXYLIC ACID
WO2019236938A1 (en) 2018-06-07 2019-12-12 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
US11203596B2 (en) * 2019-02-25 2021-12-21 Northwestern University Analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity
WO2020206234A1 (en) * 2019-04-03 2020-10-08 Northwestern University 2-difluoro substituted 4-aminocyclopentanecarboxylic acids as inhibitors of gamma-aminobutyric acid aminotransferase and human ornithine aminotransferase
US11993569B2 (en) 2020-01-23 2024-05-28 Northwestern University 3-amino-4-halocyclopentene carboxylic acids as inactivators of aminotransferases
WO2022187523A1 (en) * 2021-03-03 2022-09-09 Northwestern University (s)-3-amino-4,4-dihalocyclopent-1-enecarboxylic acid as selective inactivators of human ornithine aminotransferase
US12150998B2 (en) * 2021-04-20 2024-11-26 Bicycletx Limited Bicyclic peptide ligands specific for P-selectin
EP4387675A1 (en) * 2021-08-19 2024-06-26 N1 Life, Inc. Taxol conjugate compounds, pharmaceutical compositions comprising the same, and methods for their use
US20250171397A1 (en) * 2022-02-27 2025-05-29 Northwestern University (3s,4r)-3-amino-4-(difluoromethyl)cyclopent-1-ene-1-carboxylic acid and related compounds as selective inactivators of ornithine aminotransferase
WO2024196851A1 (en) * 2023-03-17 2024-09-26 Northwestern University Bicyclic compounds as inactivators of oat and gaba-at

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
IL177609A (en) * 2006-08-21 2015-11-30 Yaron Ilan Use of gobacoline or its analogue to produce a drug to treat liver carcinoma

Also Published As

Publication number Publication date
IL252042A0 (en) 2017-06-29
WO2016073983A2 (en) 2016-05-12
JP6867949B2 (ja) 2021-05-12
EP3215144A2 (en) 2017-09-13
EP3215144B1 (en) 2021-04-28
US20160128958A1 (en) 2016-05-12
US9603820B2 (en) 2017-03-28
MX2017006022A (es) 2017-11-17
IL252042B (en) 2020-05-31
EP3215144A4 (en) 2018-06-20
CA2966642A1 (en) 2016-05-12
ES2882126T3 (es) 2021-12-01
JP2017533964A (ja) 2017-11-16
WO2016073983A3 (en) 2016-08-11
AU2015342801A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
CA2966642C (en) Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma
US20200323866A1 (en) Ezh2 inhibitors for treating lymphoma
US12258336B2 (en) Preparation of seimicarbazide-sensitive amine oxidase inhibitor and use thereof
US12233128B2 (en) Degraders that target ALK and therapeutic uses thereof
US20190083476A1 (en) Enhancers of notch signaling and the use thereof in the treatment of cancers and malignancies medicable by upregulation of notch
CN112638866A (zh) 索拉非尼衍生物的共晶体及其制备方法
US11046684B2 (en) Compound for selectively inhibiting kinase and use thereof
Maccallini et al. Discovery of N-{3-[(ethanimidoylamino) methyl] benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma
CA2931064A1 (en) Withanolides useful for the treatment of neurodegenerative diseases
US20220226481A1 (en) Degradation of akt by conjugation of atp-competitive akt inhibitor gdc-0068 with e3 ligase ligands and methods of use
Salman et al. New Gemcitabine Derivatives as potent in vitro α-Glucosidase Inhibitors
US11203596B2 (en) Analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity
CN112513000B (zh) 新型联苯衍生物化合物及其用途
US12486246B2 (en) Replication protein A (RPA)-DNA interaction inhibitors
US12486244B2 (en) Preparation of semicarbazide-sensitive amine oxidase inhibitor and use thereof
WO2024196851A1 (en) Bicyclic compounds as inactivators of oat and gaba-at
WO2025250811A1 (en) Thymidine analogs and methods for their use in the treatments of cancer and other diseases
WO2024196853A1 (en) Substituted cyclohexene and cyclohexane inhibitors of ornithine aminotransferase
WO2024246717A1 (en) Mitochondria specific transcription inhibitors
WO2023031683A1 (en) 2,4-dioxo-1,2,3,4-tetrahydropyrimidine derivatives and their use in the treatment of tumors
HK40050156B (en) Co-crystal of sorafenib derivatives and process for preparation thereof
HK40050156A (en) Co-crystal of sorafenib derivatives and process for preparation thereof
WO2018062954A1 (ko) 사이클로필린 기능 저해제 및 사용방법

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201029

EEER Examination request

Effective date: 20201029

EEER Examination request

Effective date: 20201029

EEER Examination request

Effective date: 20201029

EEER Examination request

Effective date: 20201029

EEER Examination request

Effective date: 20201029

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241108

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241108